MicroRNA-130a regulated by HPV18 E6 promotes proliferation and invasion of cervical cancer cells by targeting TIMP2

SHANLAN YIN, QUANLE ZHANG, YUHONG WANG, SHAORU LI and RUILI HU

Department of Gynecology and Obstetrics, The First Affiliated Hospital of
Xinxiang Medical University, Weihui, Henan 453100, P.R. China

Abstract. Human papillomaviruses (HPVs) have important roles in the development and progression of cervical cancer, but the underlying mechanisms are yet to be fully elucidated. MicroRNA-130a (miR-130a) has previously been reported to promote cervical cancer growth. However, the underlying molecular mechanisms by which miR-130a promotes cervical cancer progression have remained largely elusive. In the present study, polymerase chain reaction and western blot analyses were performed to examine the expression levels of miR-130a and associated proteins. A wound healing assay and a Transwell assay were applied to study cell migration and invasion. A luciferase reporter gene assay was performed to confirm the targeting associations of miR-130a. It was observed that miR-130a was significantly upregulated in cervical cancer tissues compared with that in adjacent non-tumorous tissues. High expression of miR-130a was significantly associated with lymph node metastasis and an advanced clinical stage of cervical cancer. Furthermore, the expression of miR-130a was also higher in HPV(+) cervical cancer cell lines compared with that in HPV(-) cells. Knockdown of HPV18 E6 significantly inhibited the expression of miR-130a in HeLa cervical cancer cells. Furthermore, knockdown of miR-130a reduced the migration and invasion of HeLa cells. Tissue inhibitor of metalloproteinase 2 (TIMP2), an antagonist of matrix metalloproteinase 2 (MMP2), was identified as a novel, direct target gene of miR-130a. The expression of TIMP2 was negatively mediated by miR-130a, and HPV18 E6 inhibited the expression of TIMP2 in HeLa cells. Furthermore, knockdown of TIMP2 rescued the suppressive effects of miR-130a downregulation on the migration and invasion of HeLa cells. In summary, the present study suggests that HPV18 E6 promotes the expression of miR-130a, which further inhibits the expression of TIMP2 and promotes cervical cancer cell invasion. Therefore, HPV/miR-130a/TIMP2 signaling may be a potential target for the prevention of cervical cancer metastasis.

Introduction

Cervical cancer is one of the most common gynecological malignant tumors, and mainly occurs in developing countries, including China (1,2). It has been well-established that human papillomavirus (HPV) infection is significantly associated with the development of cervical cancer (3). Furthermore, certain oncogenes and tumor suppressors have also been identified to have key roles in cervical cancer (4-6). Elucidation of the molecular mechanisms underlying cervical cancer growth and metastasis is beneficial for the development of novel therapeutic strategies for this disease.

MicroRNAs (miRs), a class of small non-coding RNAs, can directly bind to the 3' untranslated region (UTR) of their target mRNAs, and cause RNA degradation or translation inhibition (7,8). Through mediating the expression of their target genes, miRs are involved in various cellular biological processes, including cell proliferation, differentiation, migration and invasion, as well as tumorigenesis (9-11). A large number of miRs have been demonstrated to have promoting or suppressive roles in various human cancer types, including cervical cancer, and certain miRs are strongly associated with HPV (12,13). For instance, HPV16 E7 increases the expression of miR-27b, which further promotes the proliferation and invasion of cervical carcinoma cells via directly suppressing the expression of peroxisome proliferator-activated receptor γ (14).

miR-130a has recently been demonstrated to be involved in various common human cancer types, including hepatocellular carcinoma, ovarian cancer, glioblastoma, prostate carcinoma, leukemia and cervical cancer (15). Feng *et al* (16) reported that miR-130a was regulated by nuclear factor (NF)-κB and promoted cervical cancer cell growth by inhibiting the expression of phosphatase and tensin homolog (PTEN). However, the exact role of miR-130a in cervical cancer metastasis, as well as its regulation and the underlying mechanisms, have remained to be determined.

Tissue inhibitor of metalloproteinases 2 (TIMP2) is a member of the TIMP gene family, which are natural inhibitors of the matrix metalloproteinases (MMPs), a group of peptidases involved in the degradation of the extracellular matrix

and thus cancer metastasis (17). TIMP2 was reported to be associated with cervical cancer invasion (18). However, the regulatory roles of TIMP2 in cervical cancer have remained to be fully elucidated.

The present study mainly aimed to explore the regulatory roles of miR-130a in cervical cancer metastasis and the underlying mechanisms. Furthermore, the possible link between HPV E6, miR-130a and TIMP2 in cervical cancer cells was assessed.

Materials and methods

Tissue collection. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University (Weihui, China). Cervical cancer tissues and matched adjacent normal tissues were collected from 56 cervical cancer patients at the First Affiliated Hospital of Xinxiang Medical University (Weihui, China) between September 2014 and May 2016. These cervical cancer patients were aged between 43 and 67 years (mean age, 55.7 years). Written informed consent was obtained from all patients. None of these patients received any radiation therapy or chemotherapy prior to surgery. After resection the tissues were immediately snap-frozen in liquid nitrogen and stored in liquid nitrogen until use.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from tissues and cell lines using TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA). A High-Capacity cDNA Reverse Transcription kit (cat. no. 4368813; Thermo Fisher Scientific, Inc.) was used to convert 1 μg RNA into complementary (c)DNA according to the manufacturer's protocol. For detection of miR-130a expression, the MiRNA qPCR Detection kit (cat. no. AMPR-0200; GeneCopoeia, Inc., Rockville, MD, USA) was used for amplification of cDNA on an ABI 7500 fluorescent qPCR machine (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. U6 was used as the internal reference. The primers for miR-130a (cat. no. HmiRQP0156) and U6 (cat. no. HmiRQP9001) were purchased from Fulengen (Guangzhou, China). For detecting the mRNA expression, SYBR Green qPCR Master mix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used according to the manufacturer's protocol. GAPDH was utilized as the internal reference. The primer sequences were as follows: HPV18 E6, forward 5'-AGGCGATTAAGTTGGGTA-3' and reverse 5'-CGGTAG GCGTGTACGGTG-3'; TIMP2, forward 5'-AAGCGGTCA GTGAGAAGGAAG-3' and reverse 5'-GGGGCCGTGTAG ATAAACTCTAT-3'; GAPDH, forward 5'-GGAGCGAGA TCCCTCCAAAAT-3' and reverse 5'-GGCTGTTGTCAT ACTTCTCATGG-3'. The thermocycling conditions were as follows: Initial denaturation at 95°C for 3 min and 35 cycles of denaturation at 95°C for 15 sec and annealing/elongation at 60°C for 30 sec. A melting curve analysis was performed to detect products. The relative expression was analyzed using the $2^{-\Delta\Delta Cq}$ method (19).

Cell culture. The SiHa (HPV16+), Caski (HPV16+), HeLa (HPV18+) and C33A (HPV-) human cervical cancer cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). C33A cells were cultured in RPMI1640 medium (Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.), and CaSki, SiHa and HeLa cells were cultured in Dulbecco's modified Eagle's Medium (DMEM; Thermo Fisher Scientific, Inc.) with 10% FBS at 37°C in a humidified atmosphere containing 5% CO_2.

Cell transfection. HeLa cells were transfected with negative control inhibitor (anti-NC; cat. no. CmiR-AN0001-SN; Fulengen), miR-130a inhibitor (anti-miR-130a; cat. no. HmiR-AN0156-SN-10; Fulengen), scrambled miRNA mimics (miR-NC; cat. no. CmiR0001-MR04; Fulengen), miR-130a mimics (cat. no. HmiR0170-MR04; Fulengen), NC small interfering (si)RNA (cat. no. sc-37007; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), HPV18 E6 siRNA (cat. no. 3262; Dharmacon; Thermo Fisher Scientific, Inc.), or co-transfected with miR-130a inhibitor and TIMP2 siRNA (cat. no. sc-29506; Santa Cruz Biotechnology, Inc.), or co-transfected with miR-130a inhibitor and NC siRNA using Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.) according to the manufacturer's instruction.

Western blot analysis. Cells were lysed in cold (4°C) radioimmunoprecipitation assay buffer (Thermo Fisher Scientific, Inc.) for 30 min. The protein concentration was examined using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.). Subsequently, 50 μg protein was separated by 10% SDS-PAGE and then transferred to a polyvinylidene fluoride membrane (Thermo Fisher Scientific, Inc.). The membrane was blocked in 5% non-fat dried milk in (PBS) at room temperature for 4 h. Subsequently, the membrane was incubated with mouse anti-HPV18 E6 antibody (1:500 dilution; cat. no. ab20192; Abcam, Cambridge, MA, USA), rabbit anti-human TIMP2 antibody (1:500 dilution; cat. no. ab180630; Abcam), or rabbit anti-human GAPDH antibody (1:500 dilution; cat. no. ab9485; Abcam) for at room temperature 3 h, and then incubated with goat anti-mouse secondary antibody (1:5,000 dilution; cat. no. ab97035; Abcam) or goat anti-rabbit secondary antibody (1:5,000 dilution; cat. no. ab7090; Abcam) at room temperature for 1 h. According to the manufacturer's instructions, the immune complex on the polyvinylidene fluoride membrane was detected using an Enhanced Chemiluminescence Western Blotting Kit (Thermo Fisher Scientific, Inc.). The protein expression was determined using Image-Pro Plus software 6.0 (Media Cybernetics, Inc., Rockville, MD, USA).

Wound healing assay. HeLa cells were cultured to full confluence in 6-well plates. Mitomycin C (10 μg/ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was used to treat cells at 37°C for 2 h to inhibit cell proliferation. Cells were washed with DMEM for 3 times. A wound was created by scraping the cell monolayer with a 200-μl pipette tip. After washing with DMEM twice, the cells were incubated in DMEM supplemented with 1% FBS for 24 h. Subsequently, the wound was observed under a microscope (Olympus, Tokyo, Japan).

Transwell assay. Matrigel® pre-coated Transwell chambers (BD Biosciences, Franklin Lakes, NJ, USA) were used

Table I. Association between miR-130a expression and clinicopathological characteristics of patients with cervical cancer.

| Variables | Total (n=56) | miR-130a expression | | P-value |
		Low (n=30)	High (n=26)	
Age (years)				0.786
<55	22	11	11	
≥55	34	19	15	
Tumor size (cm)				0.399
≤4 cm	38	22	16	
>4 cm	18	8	10	
Differentiation				0.191
Well/moderate	44	26	18	
Poor	12	4	8	
Clinical stage				0.025
I/II	37	24	13	
III/IV	19	6	13	
Lymph node metastasis				0.009
No	40	26	14	
Yes	16	4	12	
Distant metastasis				0.086
No	50	29	21	
Yes	6	1	5	

miR, microRNA.

to study cell invasion. HeLa cells (10^5 cells) in serum-free DMEM were seeded in the upper chambers, and DMEM with 10% FBS was added to the lower chamber. After incubation at 37°C for 24 h, the Transwell chambers were rinsed with 1% PBS. Cells on the upper surface were removed with a cotton-tipped swab, and the chamber was then stained with 0.1% crystal violet (Thermo Fisher Scientific, Inc.) at room temperature for 10 min. The invaded cells were counted under an inverted microscope (Olympus).

Bioinformatics analysis. TargetScan software 7.1 (http://www.targetscan.org) was used to predict the potential target genes of miR-130a.

Luciferase reporter gene assay. The wild-type (WT) sequence of the 3'UTR of TIMP2 containing miR-130a binding sites and the mutant-type (MT) sequence of the 3'UTR of TIMP2 lacking these miR-130a binding sites were amplified by PCR and individually subcloned into the psiCHECK-2 vector (Promega Corp., Madison, WI, USA). Lipofectamine® 2000 was used to co-transfect HeLa cells with WT or MT TIMP2 3'UTR luciferase reporter gene plasmid, and miR-NC or miR-130a mimics, respectively. In the control group, HeLa cells were transfected with WT (or MT) plasmids, without miR mimic (or miR-NC). After transfection for 48 h, the luciferase activity was determined using the Dual-Luciferase Reporter Assay System (Promega Corp.). The firefly luciferase activities were normalized to Renilla luciferase activity.

Statistical analysis. Values are expressed as the mean ± standard deviation. SPSS 19.0 (IBM Corp., Armonk, NY, USA) was used to perform statistical analysis. Differences were analyzed using Student's t-test or one-way analysis of variance followed by a post-hoc Tukey's test. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-130a is upregulated in cervical cancer and induced by HPV18 E6. n the present study, the expression levels of miR-130a were first examined in cervical cancer tissues. The results indicated that miR-130a was significantly upregulated in cervical cancer tissues compared with that in adjacent non-tumorous tissues (Fig. 1A). The cervical cancer patients included in the present study were then subdivided into a high miR-130a expression group and a low miR-130a expression group by using the mean value of miR-130a expression as the cutoff value. Further investigation revealed that high expression of miR-130a was significantly associated with lymph node metastasis and advanced clinical stage (Table I). These results suggest that the increased expression of miR-130a may contribute to the malignant progression of cervical cancer.

The expression of miR-130a was then examined in 4 common cervical cancer cell lines, namely SiHa (HPV16+), Caski (HPV16+), HeLa (HPV18+) and C33A (HPV-). The results indicated that the expression of miR-130a was significantly higher in HPV+ cervical cancer cell lines when compared with that in HPV-C33A cells (Fig. 1B). To further

Figure 1. (A) RT-qPCR was performed to examine the miR-130a expression in cervical cancer tissues compared with that in adjacent non-tumorous tissues. [**]P<0.01 vs. Adjacent. (B) RT-qPCR was performed to examine the miR-130a expression in several cervical cancer cell lines, including SiHa (HPV16+), Caski (HPV16+), HeLa (HPV18+) and C33A (HPV-). [**]P<0.01 vs. C33A. (C and D) HeLa cells were transfected with HPV18 E6 siRNA or NC siRNA. After transfection, (C) RT-qPCR and (D) western blot analysis were performed to examine the mRNA and protein expression of HPV18 E6, respectively, and (E) qPCR was performed to examine the expression of miR-130a. [**]P<0.01 vs. NC siRNA. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; HPV, human papillomavirus; siRNA, small interfering RNA; miR, microRNA; NC, negative control.

examine the association between HPV and miR-130a, HeLa cells were transfected with HPV18 E6 siRNA to knockdown its expression. After transfection, the mRNA and protein levels of HPV18 E6 were significantly decreased compared with those in the NC siRNA group (Fig. 1C and D). Of note, the miR-130a levels were also reduced after inhibition of HPV18 E6 (Fig. 1E). These results suggest that in HeLa cells, the expression of miR-130a is mediated by HPV18 E6.

Knockdown of miR-130a inhibits HeLa-cell migration and invasion. As miR-130a was highly expressed in HeLa cells, this cell line was transfected with miR-130a inhibitor to reduce its expression. After transfection, the expression of miR-130a was significantly downregulated in the anti-miR-130a group compared with that in the anti-NC group (Fig. 2A). The role of miR-130a in HeLa-cell migration and invasion was then studied. A wound healing assay indicated that knockdown of miR-130a caused a significant

decrease in HeLa-cell migration (Fig. 2B). Similarly, the Transwell assay demonstrated that inhibition of miR-130a significantly repressed HeLa-cell invasion (Fig. 2C). These results suggest that miR-130a has a promoting role in cervical cancer metastasis.

TIMP2 is a direct target gene of miR-130a. Potential target genes of miR-130a in HeLa cells were then investigated. By using a Targetscan bioinformatics prediction, TIMP2 was identified as a putative target gene of miR-130a (Fig. 3A). To verify this prediction, luciferase reporter gene plasmids driven by a WT or MT sequence of the TIMP2 3'UTR were constructed (Fig. 3B), which were employed in a luciferase reporter gene assay. As presented in Fig. 3C, the luciferase activity in HeLa cells transfected with WT TIMP2 3'UTR luciferase reporter plasmid was significantly reduced in the presence of miR-130a, while it was not reduced in the group transfected with the MT TIMP2 3'UTR luciferase reporter

Figure 2. HeLa cells were transfected with NC inhibitor or miR-130a inhibitor. (A) Reverse transcription-quantitative polymerase chain reaction was performed to examine the miR-130a expression. Furthermore, (B) a wound healing assay (magnification, x40) and (C) a Transwell assay (magnification, x400) were performed to examine cell migration and invasion, respectively. **P<0.01 vs. NC inhibitor. miR, microRNA; NC, negative control.

plasmid and miR-130a (Fig. 3C). These results indicate that TIMP2 is a direct target gene of miR-130a in HeLa cells.

The expression of TIMP2 is regulated by miR-130a in HeLa cells. Next, the effect of miR-130a on the expression of TIMP2 in HeLa cells was assessed. The results indicated that the mRNA and protein levels of TIMP2 were significantly increased after knockdown of miR-130a in HeLa cells (Fig. 4A and B). To further confirm these results, HeLa cells were transfected with miR-130a to upregulate its expression. After transfection, the expression of miR-130a was significantly higher than that in the miR-NC group (Fig. 4C). Of note, the mRNA and protein levels of TIMP2 were significantly reduced after overexpression of miR-130a (Fig. 4D and E). Therefore, the expression of TIMP2 is negatively regulated by miR-130a in HeLa cells.

HPV18 E6 regulates TIMP2 expression through miR-130a. The effect of HPV18 E6 knockdown on the expression of TIMP2 expression in HeLa cells was then assessed. As presented in Fig. 5A and B, the mRNA and protein levels of TIMP2 were significantly increased in the HPV18 E6 siRNA group, when compared with those in the NC siRNA group. Based on these and the above results, it was suggested that HPV18 E6 inhibits the expression of TIMP2 via upregulating miR-130a. To further confirm this speculation, HeLa cells were co-transfected with HPV18 E6 siRNA and miR-133a

mimics. After transfection, the expression of miR-130a was significantly increased in the HPV18 E6 siRNA+miR-133a group compared with that in the HPV18 E6 siRNA+miR-NC group (Fig. 5C). Furthermore, the mRNA and protein expression of TIMP2 was significantly reduced in the HPV18 E6 siRNA+miR-133a group compared with that in the HPV18 E6 siRNA+miR-NC group (Fig. 5D and E). Therefore, HPV18 E6 negatively regulates the expression of TIMP2 through mediation of miR-130a in HeLa cells.

TIMP2 is involved in the miR-130a-induced migration and invasion of HeLa cells. As TIMP2 is an antagonist of MMP2, it was speculated that miR-130a may exert its promoting effect on HeLa cell migration and invasion via inhibition of TIMP2 expression. To verify this speculation, HeLa cells were co-transfected with miR-130a inhibitor and TIMP2 siRNA. After transfection, the mRNA and protein levels of TIMP2 were significantly reduced in the anti-miR-130a+TIMP2 siRNA group when compared with those in the anti-miR-130a+NC siRNA group (Fig. 6A and B). Furthermore, the migration and invasion of HeLa cells was significantly increased in the anti-miR-130a+TIMP2 siRNA group compared with that in the anti-miR-130a+NC siRNA group (Fig. 6C and D). These results demonstrate that knockdown of TIMP2 attenuated, at least partly, the suppressive effects of miR-130a inhibition on the migration and invasion of HeLa cells, suggesting that

Figure 3. (A) TIMP2 was predicted to be a target gene of miR-130a. (B) The luciferase reporter gene plasmid containing WT or MT of TIMP2 3'UTR was obtained. (C) The luciferase activity was significantly reduced in the presence of miR-130a in HeLa cells transfected with WT TIMP2 3'UTR luciferase reporter plasmid, but not reduced when transfected with the MT TIMP2 3'UTR luciferase reporter plasmid. **P<0.01 vs. Control. NC, negative control; WT, wild type; MT, mutant type; UTR, untranslated region; TIMP, tissue inhibitor of metalloproteinases; miR, microRNA; hsa, *Homo sapiens*.


Figure 4. (A and B) HeLa cells were transfected with NC inhibitor or miR-130a inhibitor, and (A) RT-qPCR and (B) western blot analysis were performed to examine the mRNA and protein expression of TIMP2, respectively. **P<0.01 vs. NC inhibitor. (C-E) HeLa cells were transfected with miR-NC or miR-130a mimics. (C) RT-qPCR was performed to examine the expression of miR-130a. (D) RT-qPCR and (E) western blot analysis were used to examine the mRNA and protein expression of TIMP2, respectively. **P<0.01 vs. miR-NC. NC, negative control; TIMP, tissue inhibitor of metalloproteinases; miR, microRNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Figure 5. (A and B) HeLa cells were transfected with HPV18 E6 siRNA or NC siRNA, and (A) RT-qPCR and (B) western blot analysis were performed to examine the mRNA and protein expression of TIMP2, respectively. **P<0.01 vs. NC siRNA. (C-E) HeLa cells were co-transfected with HPV18 E6 siRNA and miR-133a mimics, or with HPV18 E6 siRNA and miR-NC. (C) RT-qPCR was performed to examine the expression of miR-130a. (D) RT-qPCR and (E) western blot analysis were applied to examine the mRNA and protein expression of TIMP2, respectively. **P<0.01 vs. HPV18 E6 siRNA+miR-NC. NC, negative control; TIMP, tissue inhibitor of metalloproteinases; miR, microRNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; HPV, human papillomavirus; siRNA, small interfering RNA.

the promoting role of miR-130a in HeLa cell migration and invasion is mediated through inhibition of the expression of TIMP2.

Discussion

The molecular mechanisms underlying miR-130a expression in cervical cancer as well as the regulatory roles of miR-130a in cervical cancer metastasis have remained largely elusive. In the present study, it was observed that miR-130a was significantly upregulated in cervical cancer tissues compared with that in adjacent non-tumor tissues. High expression of miR-130a was significantly associated with lymph node metastasis and advanced clinical stage in cervical cancer patients. Furthermore, the expression of miR-130a was also higher in HPV+ cervical cancer cell lines compared with that in HPV-cervical cancer cells. Knockdown of HPV18 E6 significantly inhibited the expression of miR-130a in HeLa cervical cancer cells. In addition, knockdown of miR-130a

reduced the migration and invasion of HeLa cells. TIMP2, an antagonist of MMP2, was identified as a novel and direct target gene of miR-130a. The expression of TIMP2 was negatively regulated by miR-130a, and HPV18 E6 inhibited the expression of TIMP2 in HeLa cells at least partly by upregulating miR-130a. Furthermore, knockdown of TIMP2 rescued the suppressive effects of miR-130a inhibition on the migration and invasion of HeLa cells.

HPV infection has been demonstrated to modulate the expression of certain miRs in cervical cancer (20,21). For instance, HPV E5, E6 and E7 directly or indirectly lead to the dysregulation of multiple miRs, including miR-34a, miR-218, miR-29a and miR-146a, which contributes to the initiation and progression of cervical cancer (22). Kong et al (20) reported that HPV E7 promotes the expression of miR-21 in HeLa cervical cancer cells, which further potentiated HeLa cell proliferation and invasion. In turn, certain miRs also regulate the expression of HPV genes (22,23). For instance, Zhang et al (23) reported that miR-129-5p reduces

Figure 6. HeLa cells were co-transfected with miR-130a inhibitor and TIMP2 siRNA, or with miR-130a inhibitor and NC siRNA. (A) reverse transcription-quantitative polymerase chain reaction and (B) western blot analysis were performed to examine the mRNA and protein expression of TIMP2, respectively. (C) A wound healing assay (magnification, x40) and (D) a Transwell assay (magnification, x400) were performed to examine cell migration and invasion, respectively. **P<0.01 vs. miR-130a inhibitor+NC siRNA. siRNA, small interfering RNA; NC, negative control; TIMP, tissue inhibitor of metalloproteinases; miR, microRNA.

the expression of HPV18 E6 and E7 by targeting signaling protein 1 in cervical cancer cells. In the present study, it was indicated that the expression of miR-130a was significantly increased in cervical cancer tissues compared with that in adjacent normal tissues, and in HPV+ cervical cancer cell lines compared with that in HPV-cervical cancer cells. In addition, the present study was the first, to the best of our knowledge, to demonstrate that the expression of miR-130a was induced by HPV18 E6 in HeLa cells. This interaction should be assessed further in future studies. In addition, high expression of miR-130a was revealed to be significantly associated with lymph node metastasis and advanced clinical stage in cervical cancer patients. Consistent with the clinical data, knockdown of miR-130a significantly decreased the migration and invasion of HeLa cells, which further suggests that miR-130a may contribute to cervical cancer metastasis.

miRs function through mediating the expression of their target genes (7). Zhang *et al* (24) reported that low concentrations of tumor necrosis factor (TNF)-α stimulated NF-κB activity and then induced miR-130a expression, while miR-130a directly targets TNF-α, and thus forms a negative

feedback regulation of NF-κB/miR-130a/TNF-α/NF-κB in cervical cancer. Feng *et al* (16) demonstrated that miR-130a promoted cervical cancer cell growth by targeting PTEN. However, other target genes of miR-130a in cervical cancer still remain to be elucidated. In the present study, TIMP2 was identified as a novel target gene of miR-130a in HeLa cells. MMPs have a key role in cancer metastasis (25). As an endogenous inhibitor of MMPs, TIMP2 has been reported to be frequently deregulated in certain human cancer types, including cervical cancer (17,26,27). MMP2 and TIMP2 expression was significantly associated with an advanced stage and poor survival of cervical cancer patients (26). The serum levels of TIMP2 were also reported to be associated with the outcome of cervical cancer patients undergoing radiochemotherapy (28). In addition, the present study indicated that the expression of TIMP2 was regulated by HPV18 E6. Similarly, Cardeal *et al* (29) also reported that HPV 16 oncoproteins induced an imbalance between MMPs and TIMP2 in primary keratinocytes, which was suggested to be a possible implication in cervical carcinogenesis.

Further investigation in the present study indicated that knockdown of TIMP2 partly attenuated the suppressive

effects of miR-130a inhibition on the migration and invasion of HeLa cells, suggesting that miR-130a promotes HeLa cell migration and invasion at least in part through inhibiting the expression of TIMP2. In addition to miR-130a, miR-20a was also reported to promote cervical cancer proliferation and metastasis *in vitro* and *in vivo* by targeting TIMP2 (30).

In summary, the results of the present study suggest that HPV18 E6 promotes the expression of miR-130a, which in turn directly inhibits the expression of TIMP2 and promotes cervical cancer cell invasion. Therefore, HPV/miR-130a/TIMP2 signaling may regarded as a potential target for the prevention of cervical cancer metastasis.

Acknowledgements

Funding

Availability of data and materials

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

Authors' contributions

SY processed tissue samples and wrote the manuscript; QZ and YW performed the experiments; SL performed statistical analysis; and RH designed the present study and revised the manuscript. The final version of the manuscript was read and approved by all authors, and each author believes that the manuscript represents their honest work.

Ethical approval and consent to participate

This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University (Weihui, China). All patients provided written informed consent.

Patient consent for publication

All written informed consents were obtained.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
3. King T: HPV, cervical cancer, and you. J Midwifery Womens Health 53: 263-264, 2008.
4. Zhang JJ, Wang DD, Du CX and Wang Y: Long noncoding RNA ANRIL promotes cervical cancer development by acting as a sponge of miR-186. Oncol Res, May 22, 2017 (Epub ahead of print).
5. Yang M, Zhai, X, Ge T, Yang C and Lou G: MiR-181a-5p promotes proliferation and invasion, and inhibits apoptosis of cervical cancer cells via regulating inositol polyphosphate-5-phosphatase A (INPP5A). Oncol Res 26: 703-712, 2018.
6. Wang C, Zhou B, Liu M, Liu Y and Gao R: miR-126-5p restoration promotes cell apoptosis in cervical cancer by targeting Bcl2l2. Oncol Res 25: 463-470, 2017.
7. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
8. John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. PLoS Biol 2: e363, 2004.
9. Zhu K, He Y, Xia C, Yan J, Hou J, Kong D, Yang Y and Zheng G: MicroRNA-15a inhibits proliferation and induces apoptosis in CNE1 nasopharyngeal carcinoma cells. Oncol Res 24: 145-151, 2016.
10. Zhou Y, Yang C, Wang K, Liu X and Liu Q: MicroRNA-33b inhibits the proliferation and migration of osteosarcoma cells via targeting hypoxia-inducible factor-1α. Oncol Res 25: 397-405, 2017.
11. Wang S, Hui Y, Li X and Jia Q: WITHDRAWN: Silencing of lncRNA-CCDC26 restrains the growth and migration of glioma cells in vitro and in vivo via targeting miR-203. Oncol Res, Jun 9, 2017 (Epub ahead of print).
12. Luo C and Qiu J: MiR-181a inhibits cervical cancer development via downregulating GRP78. Oncol Res 25: 1341-1348, 2017.
13. Gao YL, Zhao ZS, Zhang MY, Han LJ, Dong YJ and Xu B: Long noncoding RNA PVT1 facilitates cervical cancer progression via negative regulating of miR-424. Oncol Res 25: 1391-1398, 2017.
14. Zhang, S, Liu F, Mao X, Huang J, Yang J, Yin X, Wu L, Zheng L and Wang Q: Elevation of miR-27b by HPV16 E7 inhibits PPARγ expression and promotes proliferation and invasion in cervical carcinoma cells. Int J Oncol 47: 1759-1766, 2015.
15. Zhang HD, Jiang LH, Sun DW, Li J and Ji ZL: The role of miR-130a in cancer. Breast Cancer 24: 521-527, 2017.
16. Feng Y, Zhou S, Li G, Hu C, Zou W, Zhang H and Sun L: Nuclear factor-κB-dependent microRNA-130a upregulation promotes cervical cancer cell growth by targeting phosphatase and tensin homolog. Arch Biochem Biophys 598: 57-65, 2016.
17. Yi X, Guo J, Sun S, Yang P, Wang J, Li Y, Xie L, Cai J and Wang Z: EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion. Sci Rep 7: 3568, 2017.
18. Huang, Y, Li J, Xiang L, Han D, Shen X and Wu X: 17β-Oestradiol activates proteolysis and increases invasion through phosphatidylinositol 3-kinase pathway in human cervical cancer cells. Eur J Obstet Gynecol Reprod Biol 165: 307-312, 2012.
19. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
20. Kong Q, Wang W and Li P: Regulator role of HPV E7 protein on miR-21 expression in cervical carcinoma cells and its functional implication. Int J Clin Exp Pathol 8: 15808-15813, 2015.
21. Shi M, Du L, Liu D, Qian L, Hu M, Yu M, Yang Z, Zhao M, Chen C, Guo L, et al: Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 228: 148-157, 2012.
22. Zhu YK, Cheng N, Hu Y and Cen YZ: The role of microRNAs in the pathogenesis of cervical cancer and its relationship to HPV. Sheng Li Ke Xue Jin Zhan 43: 251-256, 2012 (In Chinese).
23. Zhang J, Li S, Yan Q, Chen X, Yang Y, Liu X and Wan X: Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS One 8: e81366, 2013.
24. Zhang J, Wu H, Li P, Zhao Y, Liu M and Tang H: NF-κB-modulated miR-130a targets TNF-α in cervical cancer cells. J Transl Med 12: 155, 2014.
25. Miao Y, Lu M, Yan Q, Li S and Feng Y: Inhibition of proliferation, migration, and invasion by knockdown of pyruvate kinase-M2 (PKM2) in ovarian cancer SKOV3 and OVCAR3 cells. Oncol Res 24: 463-475, 2016.
26. Braicu EI, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kümmel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W and Sehouli J: Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: Results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy. Cytokine 61: 755-758, 2013.

27. Pietruszewska W, Bojanowska-Poźniak K and Kobos J: Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: An immunohistochemical study. Otolaryngol Pol 70: 32-43, 2016.
28. Braicu EI, Gasimli K, Richter R, Nassir M, Kümmel S, Blohmer JU, Yalcinkaya I, Chekerov R, Ignat I, Ionescu A, *et al*: Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer-results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial. Anticancer Res 34: 385-391, 2014.
29. Cardeal LB, Boccardo E, Termini L, Rabachini T, Andreoli MA, di Loreto C, Longatto Filho A, Villa LL and Maria-Engler SS: HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: Possible implications in cervical carcinogenesis. PLoS One 7: e33585, 2012.
30. Zhao S, Yao D, Chen J, Ding N and Ren F: MiR-20a promotes cervical cancer proliferation and metastasis in vitro and in vivo. PLoS One 10: e0120905, 2015.